PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Saturday, June 15, 2013

NIH Censoring Expert to Prevent Criticism of Ethically Questionable NIH-Funded Study on Premature Infants

Posted on 5:02 AM by Unknown

Agency Should Encourage Open, Evidence-Based Debates to Improve Safety of Studies, Public Citizen Says in Letter

June 13, 2013

Contact: Sam Jewler (202) 588-7779; Angela Bradbery (202) 588-7741

WASHINGTON, D.C. – The National Institutes of Health (NIH) should not censor one of its experts just because he might criticize ethical lapses in an increasingly high-profile study carried out on premature babies, Public Citizen wrote today in a letter to Health and Human Services Secretary Kathleen Sebelius.

Dr. Charles Natanson, senior investigator and chief of the anesthesia section in the NIH Clinical Center’s Critical Care Medicine Department, was invited by Bloomberg BNA to co-present an educational webinar in July regarding the SUPPORT study, a NIH-funded experiment that Public Citizen recently exposed as having risked the lives of premature infants without proper parental consent. Natanson is one of the world’s leading experts on safely designing clinical trials testing treatments in critically ill patients that are usually adjusted across a wide range — for example, oxygen therapy — and measuring death as one of the primary endpoints, as was the case with this study.

In response to the invitation request from Bloomberg BNA for Natanson to participate, NIH Public Affairs Specialist Renate Myles wrote, “We are declining participation in the webinar at this time due to a forthcoming public meeting announced by HHS on [institutional review board] process for trials randomizing participants within the standard of care.”

“We are dismayed by the hypocrisy that NIH has sought to gag a renowned expert such as Dr. Natanson, who has identified serious concerns about the ethics of the study design used for the SUPPORT study,” wrote Drs. Michael Carome and Sidney Wolfe, director and senior advisor/founder of Public Citizen’s Health Research Group, respectively, in their letter, “while at the same time allowing other NIH officials the freedom to speak publicly about the study as long as their position is favorable to the NIH party line.” The letter is available at http://www.citizen.org/hrg2135.

Their letter points to a commentary piece defending the SUPPORT study that was published in the New England Journal of Medicine last week by the NIH director and two senior colleagues, including the director of the NIH institute that funded the study.

“This concerted effort by NIH officials to publicly promote a one-sided, biased defense of the study and to suppress an alternative viewpoint voiced by a well-informed NIH expert ultimately undermines the mission and integrity of the agency,” Public Citizen’s letter says.

Public Citizen urges Sebelius to immediately investigate NIH’s policies regarding participation of agency scientists in legitimate public forums and direct NIH to stop censoring experts who have well-reasoned, evidence-based critiques of the SUPPORT study or any other NIH-funded research and allow Natanson to participate in the webinar.

Information about the ethical problems with the SUPPORT study is available at http://www.citizen.org/support-study.
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ►  July (104)
    • ▼  June (81)
      • China detains GlaxoSmithKline staff for fraud: rep...
      • Get in the sack
      • Tamiflu saga continues - NYT. By Katie Thomas
      • Gouging the patient - 1boringoldman explains
      • Deen dumped
      • FDA shuts down 1,677 online pharmacies
      • Treasure Ireland contd.
      • SEC charges medical imaging firm CEO for lying on ...
      • Sleepy Seroquel
      • Federal lawmakers urge FDA to change rules to allo...
      • #UMNProud
      • Nemeroff in London - let's see the slides
      • Pfizer still on the asbestos hook
      • Meet the new Mr NICE Guy
      • Of the 86 drugs in the industry's diabetes pipelin...
      • Sometimes it is best to do nothing. A "must read "...
      • Evidence Based Medicine - Why we can’t trust clini...
      • Pharmaceutical scandal: 'You pay us £300. However,...
      • SCANDAL
      • Who's who at Quantum Pharmaceuticals?
      • Busted! No Solace for Quantum
      • Saying no to chemotherapy by Des Spence - BMJ
      • For you - special price!
      • Zalcrap contd.
      • Your puny western ads don't work on our Russian wo...
      • UK plans to cut some drug prices by up to 20 per cent
      • A Fistful of Dollars - The Cephalon off label way
      • A Smoking Pillbox: Evidence that Sgt. Bales May Ha...
      • Nine pharmas fined by EU
      • Jagemeister PR - you're doing it wrong
      • For AZ's Onglyza SAVOUR is not a saviour
      • EU fines Lundbeck for paying off pharma rivals
      • Young Law Group Announces Initiative Prosecuting A...
      • FDA Probes Deaths Linked to Long-Acting Zyprexa
      • A holy mess
      • J&J buy Aragon
      • Introducing polypill.com - medication for the mass...
      • FT - Professor turns to internet to distribute pol...
      • Shire Pharmaceuticals Ltd and Roche Products Limit...
      • NIH Censoring Expert to Prevent Criticism of Ethic...
      • Merck announces it will slash jobs at research lab...
      • AllTrials - the countdown begins
      • Experts Propose Restoring Invisible And Abandoned ...
      • The Painful Politics of Painkillers Opioids are de...
      • GSK - Little Trouble in Big China
      • No dishonour in depression
      • Healing the Overwhelmed Physician - by Jerry Avorn
      • GlaxoSmithKline Fires China R&D Boss for 'Misrepre...
      • Charles Nemeroff - Honoured in Britain, the US psy...
      • How Big Pharma Drives Up Medicare Spending Without...
      • Walgreens pays record $80 million settlement for i...
      • Has pancreatic damage from glucagon suppressing di...
      • Austerity is bull!
      • Obama administration reverses course on Plan B pill
      • Corporate Whistle Blower Center Now Urges Pharmace...
      • Endo Implodes
      • Introducing OTC Toolbox
      • Pearl bought
      • Johnson & Johnson seeks home court advantage in Ty...
      • The geography of antidepressant, antipsychotic, an...
      • One to watch - Dispatches, Channel 4, Monday June ...
      • How much is your doctor making from Big Pharma?
      • Not just Bad - Ineffective Pharma!
      • Not just Bad - Filthy Pharma
      • Big data to sniff out drug marketing fraud
      • Dr Sidney Wolfe retires with a bang!
      • Kerching!
      • No-user, no cry
      • Nine pharma firms face EU fines over pay-for-delay...
      • Here for a good time or a long time?
      • Yet another J&J recall!
      • The Myth of the New
      • Keepy-uppy!
      • Meet the Doctor Big Pharma Can't Shut Up
      • In Memoriam: Barbara A. Brenner, 1951-2013
      • Pink Ribbons Inc. - watch the movie
      • Gouging 101 spotted by Dr Judy Stone
      • Summer Reading contd. Blood Medicine by Kathleen S...
      • Corporate fines are puny
      • "Brad Abbey" on Ben Goldacre
      • AllTrials contd. - D Day for comments - June 10th
    • ►  May (5)
Powered by Blogger.